HbA1c blood test
Hemoglobin A1c. Also called: A1C, Glycated hemoglobin, Glycohemoglobin
HbA1c shows your average blood sugar over the past two to three months. It is used to diagnose prediabetes and diabetes and to track treatment. GLP-1 drugs lower it; some GH-axis peptides and pasireotide raise it.
At a glance
| What it measures | The share of hemoglobin in red blood cells that has glucose attached. It reflects average blood sugar over roughly the past three months. |
|---|---|
| Sample | Whole blood (EDTA tube). No fasting needed. |
| Decision limits | Normal below 5.7%; prediabetes 5.7-6.4%; diabetes 6.5% or higher (NGSP-certified test). |
| Peptides that move it | Lowered by GLP-1 drugs such as Semaglutide and Tirzepatide. Raised by Pasireotide, and Tesamorelin increased the share of people reaching 6.5%. |
| Lab code | LOINC 4548-4 (Labcorp 001453, Quest 496) |
What is HbA1c?
HbA1c is hemoglobin A with glucose stably attached to the end of its beta chain. The more glucose in your blood over the life of a red cell, the more HbA1c forms, so the test gives a long-run average rather than a snapshot.
It has been used to judge glucose control since the mid-1970s. Labs use it to diagnose diabetes and prediabetes and to follow treatment.
How it is made and regulated
Where it is made
Glucose attaches to the N-terminal valine of hemoglobin's beta chain without any enzyme. This happens continuously inside red blood cells, at a rate set by how much glucose is around.
What controls it
HbA1c follows average blood sugar. In five hospitalized patients, bringing fasting blood sugar down from 343 to 84 mg/dL took HbA1c from 9.8% to 5.8%. In 507 people wearing glucose monitors, average glucose (mg/dL) was 28.7 x HbA1c - 46.7 (R2 0.84).
How it travels in the blood
HbA1c stays inside red blood cells, so the test uses whole blood rather than serum. Labcorp notes that glycated fetal hemoglobin (HbF) is not detected, so very high HbF (over 10%) can give lower-than-expected results.
How long it lasts
Glycation happens over the red cell's roughly 120-day life. The result is weighted toward recent weeks: about half comes from the last 30 days and about 10% from 90 to 120 days ago.
Sources: [4]
What it does
HbA1c is a marker of glucose exposure. Lowering it reduces complications: in type 1 diabetes, intensive treatment cut new retinopathy by 76%, and in type 2 diabetes intensive control (HbA1c 7.0% vs 7.9%) cut microvascular complications by 25%.
Reference ranges
HbA1c ranges are decision limits from the American Diabetes Association, not population percentiles, so Labcorp and Quest report almost the same cut-offs.
Labcorp (test 001453)
| Group | Range (%) |
|---|---|
| Hemoglobin A1c (normal) | 4.8-5.6 |
| Prediabetes | 5.7-6.4 |
| Diabetes | 6.5 or higher |
| Glycemic control goal for adults with diabetes | Below 7.0 |
Labcorp warns that anything shortening red-cell survival (hemolytic anemia, blood loss, pregnancy, homozygous sickle cell) lowers HbA1c, and that hemoglobin variants need care in interpretation.
Quest Diagnostics (test 496)
| Group | Range (%) |
|---|---|
| Reference range | Below 5.7 |
Quest states that its interpretive ranges are based on ADA guidelines. Read from Quest's test directory for the East service area.
Use the cut-offs printed on your report. Results from tests that are not NGSP-certified should not be compared with these limits.
Units: US labs report HbA1c in NGSP percent; the IFCC reference method measures the same molecule more specifically, and the two are linked by NGSP % = 0.915 x IFCC % + 2.15. Labs outside the US often report mmol/mol: 6.5% is 48 mmol/mol. [9]
Is there an "optimal" range?
Below 5.7% counts as normal, but some clinics push lower targets. Studies in people without diabetes do not agree on whether lower is always better.
Lower is better, all the way down
People under 5% had the lowest rates in one cohort
EPIC-Norfolk cohort (4,662 men and 5,570 women aged 45-79)
Risk of heart disease and death rose steadily across the whole HbA1c range, including in people without diabetes. Each 1-point rise went with about 24-28% higher risk of death.
Sources: [10]
Very low is not clearly better
Reference group 5.0-5.5%; death risk J-shaped
ARIC study (11,092 adults without diabetes)
Diabetes and heart-disease risk rose above 5.5%, but death from any cause had a J-shaped curve, rising again at the lowest values.
Sources: [11]
The J-shape is mostly confounding
Pooled analysis of six cohorts (28,681 adults aged 50 and older without diabetes)
The link with heart attack and stroke was linear, and pooled estimates for very low HbA1c were not significant. In the one cohort with a clear J-shape, the extra deaths at very low HbA1c disappeared after accounting for iron-deficiency anemia, liver function, alcohol, BMI and race.
Sources: [12]
What raises it
| Factor | How | How much |
|---|---|---|
| High average blood sugar (diabetes, prediabetes)Condition | More glucose means more hemoglobin gets glycated. | Fasting sugar of 343 mg/dL went with HbA1c of 9.8%; at 84 mg/dL it fell to 5.8% (5 patients) [2] |
| Iron-deficiency anemiaCondition | Iron deficiency raises HbA1c without a matching rise in glucose. | 5.59% vs 5.34% in people without anemia (2,831 people) [13] |
| HypothyroidismCondition | HbA1c was higher in people with an underactive thyroid and fell after treatment, without a change in glucose, possibly through changes in red-cell turnover. | No published magnitude [14] |
| Aspirin (some assays)Medication | Aspirin raised the result on one of three methods tested; vitamins C and E had no effect. | +0.17% after 4 months on one HPLC method (not clinically relevant) [15] |
| Race and ethnicityPhysiology | Racial and ethnic differences in HbA1c have been described that glucose levels do not explain. | No published magnitude [16] |
| GH-axis and somatostatin-analog peptidesPeptide | Some peptides worsen glucose control. See the peptide table below for each one. | Pasireotide: mean HbA1c 5.8% to 7.2% over 12 months [17] |
What lowers it
| Factor | How | How much |
|---|---|---|
| Shorter red-cell life (hemolytic anemia, blood loss, pregnancy)Condition | Red cells have less time to collect glucose, so HbA1c reads low for the true glucose level. | No published magnitude [4] |
| Sickle cell traitPhysiology | For the same fasting glucose, HbA1c reads lower in people with sickle cell trait. | 5.72% vs 6.01% (difference -0.29%) in 4,620 African American adults [18] |
| High fetal hemoglobin (HbF over 10%)Physiology | Glycated HbF is not detected by the immunoassay, so very high HbF gives lower-than-expected values. | No published magnitude [4] |
| Better glucose controlLifestyle | Intensive treatment keeps HbA1c lower over years. | 7.0% vs 7.9% over 10 years with intensive vs conventional treatment (3,867 people with type 2 diabetes) [8] |
| GLP-1, GIP and amylin-based peptidesPeptide | See the peptide table below for each one. | Semaglutide: -1.6% vs -0.1% on placebo at 30 weeks [19] |
Peptides that affect HbA1c
How each peptide in our library has been shown to change HbA1c, strongest evidence first. Most results come from people with type 2 diabetes, where HbA1c starts high; changes in people without diabetes are smaller.
| Peptide | Effect on HbA1c | Size of effect | Evidence |
|---|---|---|---|
| Anamorelin | Raises | No figure in the abstract; HbA1c rose by week 3 in a 13-patient prospective studyOral ghrelin-receptor agonist studied for cancer-related weight loss. [20] | Human trials |
| Capromorelin | Raises | No figure in the abstract; reported as a small increaseOral GH secretagogue tested in older adults. [21] | Human trials |
| Leuprolide | Raises | No figure in the abstract; HbA1c rose at day 85 (not day 169) in 1,102 menGnRH agonist used for androgen deprivation. Pooled data from men on leuprolide, leuprolide plus bicalutamide, or abarelix; fasting glucose did not change. [22] | Human trials |
| Pasireotide | Raises | Mean HbA1c rose from 5.8% to 7.2% after 12 months (Cushing's disease, extension study)Somatostatin analog. In drug-naive acromegaly, the Signifor LAR label reports diabetes prevalence rising from 30% to 60% at month 12. [17] [23] | Human trials |
| Albiglutide | Lowers | -0.84% (30 mg) and -1.04% (50 mg) vs placebo at 52 weeks as the only diabetes drug (309 adults)Weekly GLP-1 receptor agonist (HARMONY 2 trial). [24] | Human trials |
| Amycretin (Zenagamtide) | Lowers | Up to -1.56% vs placebo with weekly injections (40 mg) and up to -1.09% with daily tablets (50 mg) at 36 weeks (type 2 diabetes)GLP-1 and amylin receptor agonist (also called zenagamtide). Two phase 2 trials. [25] [26] | Human trials |
| ARA-290 | Lowers | No figure in the abstract; HbA1c improved over the 56-day observation periodNon-erythropoietic peptide derived from erythropoietin, tested in people with type 2 diabetes and painful neuropathy. [27] | Human trials |
| Cagrilintide | Lowers | -0.9 percentage points at 32 weeks on cagrilintide 2.4 mg alone; -2.2 when combined with semaglutide (CagriSema)Weekly amylin analog, phase 2 in type 2 diabetes. [28] | Human trials |
| Carnosine | Lowers | -0.91% (90% credible interval -1.46 to -0.39), Bayesian meta-analysis of human studies of carnosine or beta-alanineDipeptide supplement. Only four human studies; most data in the same review are from rodents. [29] | Human trials |
| Cotadutide | Lowers | -0.67% to -0.77% vs placebo across doses (meta-analysis of randomized trials in type 2 diabetes)Daily GLP-1 and glucagon receptor agonist. The authors rated the certainty of evidence very low to low. [30] [31] | Human trials |
| Lixisenatide | Lowers | -0.54% and -0.66% vs placebo at 12 weeks (two dose-escalation schemes, 361 adults, baseline 8.0%)Daily GLP-1 receptor agonist, tested as the only diabetes drug. [32] | Human trials |
| Maridebart Cafraglutide | Lowers | -1.2 to -1.6 percentage points vs +0.1 on placebo (phase 2, people with obesity and type 2 diabetes)Monthly GLP-1 agonist and GIP receptor antagonist. [33] | Human trials |
| Mazdutide | Lowers | -1.57% (4 mg) and -2.15% (6 mg) vs -0.14% on placebo at 24 weeks (320 adults with type 2 diabetes, baseline 8.24%)Weekly GLP-1 and glucagon receptor agonist (phase 3, China). [34] | Human trials |
| Retatrutide | Lowers | -1.69% (4 mg) to -1.94% (12 mg) vs -0.81% on placebo at 40 weeks (phase 3, baseline 7.9%)Weekly GIP, GLP-1 and glucagon receptor agonist. Placebo-adjusted differences were -0.88% to -1.12%. In phase 2 the 12 mg dose lowered HbA1c by 2.02% at 24 weeks. [35] [36] | Human trials |
| Survodutide | Lowers | -0.91% to -1.71% at 16 weeks across six dose groups (phase 2, baseline 8.07%, on metformin)Weekly glucagon and GLP-1 receptor agonist. A low dose matched semaglutide 1 mg (-1.46% vs -1.47%). [37] | Human trials |
| Tesamorelin | Raises | HbA1c reached 6.5% or higher by week 26 in 5% vs 1% on placebo; diabetes-risk odds ratio 3.3 (CI 1.4 to 9.6)GHRH analog (Egrifta SV); the label says to check glucose status before and during treatment. In a 12-week trial in people with type 2 diabetes, HbA1c did not differ from placebo. [38] [39] | FDA label |
| Dulaglutide | Lowers | -0.7% (0.75 mg) and -0.8% (1.5 mg) at 26 weeks as the only diabetes drug (baseline 7.6%), vs -0.6% on metforminWeekly GLP-1 receptor agonist (Trulicity). [40] | FDA label |
| Exenatide | Lowers | -0.7% (5 µg) and -0.9% (10 µg twice daily) vs -0.2% on placebo at 24 weeks as the only diabetes drugTwice-daily GLP-1 receptor agonist (Byetta). Placebo-adjusted differences were -0.5% and -0.7%. [41] | FDA label |
| Insulin | Lowers | -0.5 percentage points at 52 weeks when insulin glargine was added to oral drugs (from 9.0%), similar to NPH insulin (-0.4)Label trials compare insulin types (here, glargine vs NPH) rather than insulin against no insulin. [42] | FDA label |
| Leptin | Lowers | -2.0 percentage points at 12 months (from 8.5%, 35 people with generalized lipodystrophy); -2.4 when baseline was 7% or higherMetreleptin (Myalept) in people with generalized lipodystrophy, who make almost no leptin. [43] | FDA label |
| Liraglutide | Lowers | -1.1% (1.8 mg) and -0.8% (1.2 mg) at 52 weeks as the only diabetes drug (baseline 8.2%), vs -0.5% on glimepirideDaily GLP-1 receptor agonist (Victoza). [44] | FDA label |
| Pramlintide | Lowers | -0.66% vs -0.32% on placebo at 6 months (120 µg with insulin, type 2 diabetes); placebo-adjusted -0.34%Amylin analog given with mealtime insulin (Symlin). A 52-week trial saw -0.68% and -0.62% at weeks 26 and 52. [45] [46] | FDA label |
| Semaglutide | Lowers | -1.4% (0.5 mg) and -1.6% (1 mg) vs -0.1% on placebo at 30 weeks as the only diabetes drug (baseline about 8.0%)Weekly GLP-1 receptor agonist (Ozempic). Placebo-adjusted differences were -1.2% and -1.4%. [19] | FDA label |
| Tirzepatide | Lowers | -1.8% (5 mg) and -1.7% (10 and 15 mg) vs -0.1% on placebo at 40 weeks as the only diabetes drug (baseline about 8.0%)Weekly GIP and GLP-1 receptor agonist (Mounjaro). 82% of people on 5 mg reached HbA1c below 7%, vs 23% on placebo. [47] | FDA label |
What high or low results can mean
A high result
On an NGSP-certified test, 6.5% or higher meets the diagnostic level for diabetes and 5.7-6.4% is prediabetes. People with prediabetes should be retested yearly.
- Diabetes or prediabetes
- Iron-deficiency anemia
- Hypothyroidism
- Some medicines, including pasireotide and growth hormone-axis drugs
A low result
A low HbA1c usually reflects good glucose control, but it can also mean red cells are living shorter lives, which makes the test read low.
- Hemolytic anemia or recent blood loss
- Pregnancy
- Sickle cell trait or other hemoglobin variants
- Very high fetal hemoglobin
How the test works
| Sample | Whole blood in an EDTA (lavender-top) tube. Labcorp also accepts lithium heparin or sodium fluoride tubes. |
|---|---|
| Fasting | Neither Labcorp nor Quest lists fasting for this test; it reflects months of glucose, not your last meal. |
| Timing | The ADA recommends testing at least twice a year when glucose is stable, and every three months when it is not at goal or treatment has changed. |
| Lab differences | Use a lab whose method is NGSP-certified and traceable to the DCCT assay. The IFCC reference method gives lower numbers than most routine methods because it is more specific, which is why NGSP and IFCC results differ. |
| Retesting | Labcorp treats a change of 0.5 percentage points as clinically significant. Within one person, HbA1c varies only about 2.5% from week to week, so a change of about 10% between tests is needed to stand out from noise. |
| Labcorp order code | 001453: Hemoglobin (Hb) A1c |
| Quest Diagnostics order code | 496: Hemoglobin A1c |
| LOINC codes |
|
History
HbA1c went from an odd hemoglobin fraction to the standard measure of diabetes control in about 40 years.
- 1968Rahbar reports an abnormal hemoglobin in the red cells of people with diabetes. [51]
- 1976Koenig and colleagues show that hemoglobin AIc falls as diabetes control improves, tracking blood sugar over the previous weeks to months. [2]
- 1993The DCCT shows that intensive treatment in type 1 diabetes cuts new retinopathy by 76%; a year later the ADA sets glycemic treatment goals. [7] [49]
- 1996The National Glycohemoglobin Standardization Program (NGSP) starts certifying methods as traceable to the DCCT assay. [49]
- 2002The IFCC approves a reference method that measures the glycated N-terminal peptide of the beta chain directly. [1]
- 2004A method-comparison study links the IFCC reference method to the US, Japanese and Swedish scales with fixed equations. [9]
- 2008The ADAG study converts HbA1c into an estimated average glucose in mg/dL. [5]
- 2009An International Expert Committee reports on the role of the A1C assay in diagnosing diabetes. [52]
FAQ
Do I need to fast for an HbA1c test?
No. Neither Labcorp nor Quest lists fasting for HbA1c, because it reflects glucose over about three months rather than your last meal.
What time period does HbA1c cover?
Roughly the past three months, the life of a red blood cell, but it is weighted toward recent weeks: about half the result comes from the last 30 days.
Sources: [4]
What is a normal HbA1c?
Below 5.7%. Labcorp lists 4.8-5.6% as normal, 5.7-6.4% as prediabetes and 6.5% or higher as diabetes, based on ADA guidelines.
How does HbA1c translate into average blood sugar?
The ADAG study, which compared HbA1c with three months of glucose monitoring in 507 people, found average glucose (mg/dL) = 28.7 x HbA1c - 46.7. Labs call this the estimated average glucose (eAG).
Sources: [5]
My report says mmol/mol. How does that compare?
That is the IFCC unit used in many countries. 6.5% equals 48 mmol/mol and 6.0% equals 42 mmol/mol.
How often should HbA1c be checked?
The ADA recommends at least twice a year when glucose is stable, and every three months when it is not at goal or treatment has changed. People with prediabetes should be tested yearly.
Can anemia change my HbA1c?
Yes, in both directions. Iron-deficiency anemia pushed HbA1c up (5.59% vs 5.34%), while conditions that shorten red-cell life, such as hemolytic anemia or blood loss, push it down.
Does sickle cell trait affect HbA1c?
Yes. For the same fasting glucose, people with sickle cell trait had HbA1c about 0.3 percentage points lower. Labs advise extra care interpreting results with hemoglobin variants.
Do supplements like vitamin C or aspirin change the result?
In a 4-month trial, vitamins C and E had no effect on HbA1c with any of three methods. Aspirin raised it by 0.17% on one HPLC method, which the authors called not clinically relevant.
Sources: [15]
Can thyroid problems affect HbA1c?
An underactive thyroid was linked to higher HbA1c that fell after treatment, without a change in glucose. The authors point to changes in red-cell turnover.
Sources: [14]
Is HbA1c better than fasting glucose?
In 11,092 adults without diabetes, HbA1c predicted diabetes about as well as fasting glucose and predicted heart disease and death more strongly.
Sources: [11]
How big a change between tests matters?
Labcorp treats a change of 0.5 percentage points as clinically significant. Studies of healthy people put the change needed to stand out from normal variation at about 5-10% of the value, depending on the method.
Can peptides lower HbA1c?
Several do. In type 2 diabetes, Semaglutide lowered HbA1c by 1.6% (vs 0.1% on placebo) and Tirzepatide by 1.8% (vs 0.1%). Some peptides do the opposite: Pasireotide raised average HbA1c from 5.8% to 7.2%.
References
- Jeppsson JO, Kobold U, Barr J, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med. 2002;40(1):78-89. PMID 11916276
- Koenig RJ, Peterson CM, Jones RL, et al. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med. 1976;295(8):417-20. PMID 934240
- Saudek CD, Brick JC. The clinical use of hemoglobin A1c. J Diabetes Sci Technol. 2009;3(4):629-34. PMID 20144304
- Labcorp. Test 001453: Hemoglobin (Hb) A1c. Reference range, specimen requirements, methodology, limitations and LOINC map. labcorp.com/tests/001453/hemoglobin-hb-a1c
- Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473-8. PMID 18540046
- Quest Diagnostics. Test 496: Hemoglobin A1c. Test directory entry (East service area): methodology, specimen, reference range and LOINC. testdirectory.questdiagnostics.com/test/test-detail/496/hemoglobin-a1c?cc=PHP
- Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86. PMID 8366922
- Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53. PMID 9742976
- Hoelzel W, Weykamp C, Jeppsson JO, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem. 2004;50(1):166-74. PMID 14709644
- Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141(6):413-20. PMID 15381514
- Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800-11. PMID 20200384
- Schöttker B, Rathmann W, Herder C, et al. HbA1c levels in non-diabetic older adults - No J-shaped associations with primary cardiovascular events, cardiovascular and all-cause mortality after adjustment for confounders in a meta-analysis of individual participant data from six cohort studies. BMC Med. 2016;14:26. PMID 26867584
- Intra J, Limonta G, Cappellini F, et al. Glycosylated Hemoglobin in Subjects Affected by Iron-Deficiency Anemia. Diabetes Metab J. 2019;43(4):539-544. PMID 30604593
- Bhattacharjee R, Thukral A, Chakraborty PP, et al. Effects of thyroid status on glycated hemoglobin. Indian J Endocrinol Metab. 2017;21(1):26-30. PMID 28217494
- Camargo JL, Stifft J, Gross JL. The effect of aspirin and vitamins C and E on HbA1c assays. Clin Chim Acta. 2006;372(1-2):206-9. PMID 16698007
- Herman WH. Do race and ethnicity impact hemoglobin A1c independent of glycemia?. J Diabetes Sci Technol. 2009;3(4):656-60. PMID 20144308
- Schopohl J, Gu F, Rubens R, et al. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. Pituitary. 2015;18(5):604-12. PMID 25537481
- Lacy ME, Wellenius GA, Sumner AE, et al. Association of Sickle Cell Trait With Hemoglobin A1c in African Americans. JAMA. 2017;317(5):507-515. PMID 28170479
- OZEMPIC (semaglutide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- Kuraoka S, Iwamuro M, Satomi T, et al. Endocrinological Changes after Anamorelin Administration in Patients with Gastrointestinal Cancer. Acta Med Okayama. 2023;77(3):235-241. PMID 37357624
- White HK, Petrie CD, Landschulz W, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab. 2009;94(4):1198-206. PMID 19174493
- Yannucci J, Manola J, Garnick MB, et al. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol. 2006;176(2):520-5. PMID 16813881
- SIGNIFOR LAR (pasireotide) for injectable suspension, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0aad470-3f38-af97-e053-2995a90a383a
- Nauck MA, Stewart MW, Perkins C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia. 2016;59(2):266-74. PMID 26577795
- Mora P, Aroda VR, Asong M, et al. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026;408(10555):621-635. PMID 42532080
- Mora P, Aroda VR, Asong M, et al. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026;408(10555):607-620. PMID 42532079
- Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015;20(1):658-66. PMID 25387363
- Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730. PMID 37364590
- Matthews JJ, Dolan E, Swinton PA, et al. Effect of Carnosine or β-Alanine Supplementation on Markers of Glycemic Control and Insulin Resistance in Humans and Animals: A Systematic Review and Meta-analysis. Adv Nutr. 2021;12(6):2216-2231. PMID 34333586
- Kamrul-Hasan ABM, Dutta D, Nagendra L, et al. Glycemic control, weight-loss effects, and safety of cotadutide in individuals with type 2 diabetes: A systematic review and meta-analysis. World J Diabetes. 2025;16(12):112830. PMID 41480597
- Nahra R, Wang T, Gadde KM, et al. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care. 2021;44(6):1433-1442. PMID 34016612
- Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35(6):1225-31. PMID 22432104
- Jastreboff AM, Ryan DH, Bays HE, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025;393(9):843-857. PMID 40549887
- Zhu D, Zhao J, Cai H, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026;652(8108):174-180. PMID 41407859
- Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413. PMID 42250575
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PMID 37385280
- Blüher M, Rosenstock J, Hoefler J, et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024;67(3):470-482. PMID 38095657
- EGRIFTA SV (tesamorelin) for injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. PMID 28617838
- TRULICITY (dulaglutide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
- BYETTA (exenatide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f
- LANTUS (insulin glargine) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5e07a0c-7e14-4756-9152-9fea485d654a
- MYALEPT (metreleptin) for injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3b50bbd-140b-425c-b5ec-d4682aad62bc
- VICTOZA (liraglutide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
- SYMLIN (pramlintide acetate) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff
- Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26(3):784-90. PMID 12610038
- MOUNJARO (tirzepatide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- LOINC 4548-4: Hemoglobin A1c/Hemoglobin.total in Blood. Regenstrief Institute. Record checked through the NLM Clinical Table Search Service. loinc.org/4548-4
- Little RR, Rohlfing CL, Wiedmeyer HM, et al. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem. 2001;47(11):1985-92. PMID 11673367
- Braga F, Dolci A, Montagnana M, et al. Revaluation of biological variation of glycated hemoglobin (HbA(1c)) using an accurately designed protocol and an assay traceable to the IFCC reference system. Clin Chim Acta. 2011;412(15-16):1412-6. PMID 21524644
- Rahbar S. An abnormal hemoglobin in red cells of diabetics. Clin Chim Acta. 1968;22(2):296-8. PMID 5687098
- International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327-34. PMID 19502545
- Ucar F, Erden G, Ginis Z, et al. Estimation of biological variation and reference change value of glycated hemoglobin (HbA(1c)) when two analytical methods are used. Clin Biochem. 2013;46(15):1548-53. PMID 23732479
Educational information, not medical advice. Lab ranges and test codes were checked on October 29, 2026. Always use the range printed on your own report, and talk to a clinician about your results.